View Older Stories View More Recent Stories

Apr 30, 2019 07:45AM European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Apr 30, 2019 07:08AM AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting
Apr 25, 2019 07:42AM AbbVie Reports First-Quarter 2019 Financial Results
Apr 23, 2019 06:19PM AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Apr 3, 2019 08:00AM AbbVie to Host First-Quarter 2019 Earnings Conference Call
Mar 26, 2019 01:00AM AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Jap
Mar 19, 2019 08:46AM AbbVie (ABBV) Announces Partial Clinical Hold on VENCLEXTA/VENCLYXTO Trials
Mar 19, 2019 08:45AM AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program
Mar 7, 2019 08:47AM AbbVie (ABBV) Announces Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated CLL Patients
Mar 7, 2019 08:46AM AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients
Mar 1, 2019 08:00AM AbbVie to Present at the Barclays Global Healthcare Conference
Mar 1, 2019 07:06AM AbbVie (ABBV) Receives CHMP Positive Opinion for Risankizumab for Treatment of Moderate to Severe Plaque Psoriasis
Mar 1, 2019 07:00AM AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis
Feb 28, 2019 08:00AM AbbVie to Present at the Cowen Health Care Conference
Feb 25, 2019 08:32AM AbbVie (ABBV) to Showcase Scientific Innovation, Research Advancements Across Dermatology Portfolio at AAD
Feb 25, 2019 08:31AM AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting
Feb 22, 2019 08:01AM AbbVie (ABBV), Voyager Therapeutics (VYGR) Enter Pact to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
Feb 22, 2019 08:00AM AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
Feb 21, 2019 01:21PM AbbVie Declares Quarterly Dividend
Feb 19, 2019 08:37AM AbbVie (ABBV) Announces NDA Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe RA
Feb 19, 2019 08:31AM AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Feb 11, 2019 08:05AM AbbVie (ABBV), Teneobio Announce Pact to Develop a New Treatment for Multiple Myeloma
Feb 11, 2019 08:00AM AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
Jan 28, 2019 07:01AM AbbVie (ABBV) Announces U.S. FDA Approval of IMBRUVICA Plus Obinutuzumab for CLL/SLL
Jan 28, 2019 07:00AM AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymp
Jan 25, 2019 07:42AM AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results
Jan 18, 2019 04:31PM AbbVie (ABBV) Phase 3 Study of Ibrutinib in Metastatic Pancreatic Did Not Meet its Primary Endpoint
Jan 18, 2019 04:29PM AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
Jan 3, 2019 08:44AM AbbVie (ABBV), Tizona Therapeutics Report Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Jan 3, 2019 08:30AM AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Jan 3, 2019 08:00AM AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call
Dec 24, 2018 09:42AM AbbVie (ABBV) to License Lupin's MALT1 Inhibitor Program to Develop & Commercialize Novel Oncology Drug to Treat Hematological Cancers
Dec 20, 2018 08:51AM AbbVie (ABBV) Submits NDA to U.S. FDA and MAA to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Dec 20, 2018 08:50AM AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Dec 20, 2018 08:00AM AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 17, 2018 09:00AM AbbVie Announces Executive Leadership Changes
Dec 13, 2018 01:00PM AbbVie (ABBV) Announces $5B Increase in Buyback Plan
Dec 13, 2018 01:00PM AbbVie Announces $5 Billion Increase to Stock Repurchase Program
Dec 11, 2018 08:14AM Symboli Security Token Offering (STO) Showcasing the First Cannabis Dividend®
Dec 5, 2018 04:47PM AbbVie (ABBV) Phase 3 Trial of Rova-T Halted After Shorter Overall Survival
Dec 5, 2018 04:01PM Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted
Dec 4, 2018 11:54AM AbbVie (ABBV) Says IMBRUVICA Combo Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR in Some CLL Patients
Dec 4, 2018 11:52AM IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic
Dec 3, 2018 02:27PM AbbVie (ABBV) IMBRUVICA Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement PFS Over Standard Chemoimmunotherapy for Previously Untreated CLL/SLL
Dec 3, 2018 02:17PM IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab f
Dec 3, 2018 06:10AM AbbVie (ABBV) Reports New Data from Phase 3 MURANO Trial of VENCLEXTA/VENCLYXTO (venetoclax) in Combination with Rituximab
Dec 2, 2018 12:00PM IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a
Dec 1, 2018 05:47PM AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed
Nov 30, 2018 10:01AM Pfizer (PFE) Reaches Global Agreement with AbbVie (ABBV) on Adalimumab Biosimilar
Nov 30, 2018 10:00AM AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer
View More Recent Stories View Older Stories